For more information on this report please contact ediz.ibrahim@visiongain.com (+44 (0) 2075499976) or refer to our website: http://www.visiongain.com/Report/1159/Translational-Regenerative-Medicine-Market-Prospects-2014-2024
Venta de Ropa por Catalogo – Venta para uso personal o para negocio / Aproveche, inicie o surta su negocio con productos espectaculares (Jeans, Blusas, Tejidos, Pijamas, Ropa Intima y muchos productos mas …)
Para aclarar sus dudas o inquietudes escriba o info@linnova.net o utilice el Formulario de Contacto de la pagina web www.linnova.net
Venta de Ropa por Catalogo – Venta para uso personal o para negocio / Aproveche, inicie o surta su negocio con productos espectaculares (Jeans, Blusas, Tejidos, Pijamas, Ropa Intima y muchos productos mas …)
Para aclarar sus dudas o inquietudes escriba o info@linnova.net o utilice el Formulario de Contacto de la pagina web www.linnova.net
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
PHP Frameworks: I want to break free (IPC Berlin 2024)Ralf Eggert
In this presentation, we examine the challenges and limitations of relying too heavily on PHP frameworks in web development. We discuss the history of PHP and its frameworks to understand how this dependence has evolved. The focus will be on providing concrete tips and strategies to reduce reliance on these frameworks, based on real-world examples and practical considerations. The goal is to equip developers with the skills and knowledge to create more flexible and future-proof web applications. We'll explore the importance of maintaining autonomy in a rapidly changing tech landscape and how to make informed decisions in PHP development.
This talk is aimed at encouraging a more independent approach to using PHP frameworks, moving towards a more flexible and future-proof approach to PHP development.
Essentials of Automations: The Art of Triggers and Actions in FMESafe Software
In this second installment of our Essentials of Automations webinar series, we’ll explore the landscape of triggers and actions, guiding you through the nuances of authoring and adapting workspaces for seamless automations. Gain an understanding of the full spectrum of triggers and actions available in FME, empowering you to enhance your workspaces for efficient automation.
We’ll kick things off by showcasing the most commonly used event-based triggers, introducing you to various automation workflows like manual triggers, schedules, directory watchers, and more. Plus, see how these elements play out in real scenarios.
Whether you’re tweaking your current setup or building from the ground up, this session will arm you with the tools and insights needed to transform your FME usage into a powerhouse of productivity. Join us to discover effective strategies that simplify complex processes, enhancing your productivity and transforming your data management practices with FME. Let’s turn complexity into clarity and make your workspaces work wonders!
Why You Should Replace Windows 11 with Nitrux Linux 3.5.0 for enhanced perfor...SOFTTECHHUB
The choice of an operating system plays a pivotal role in shaping our computing experience. For decades, Microsoft's Windows has dominated the market, offering a familiar and widely adopted platform for personal and professional use. However, as technological advancements continue to push the boundaries of innovation, alternative operating systems have emerged, challenging the status quo and offering users a fresh perspective on computing.
One such alternative that has garnered significant attention and acclaim is Nitrux Linux 3.5.0, a sleek, powerful, and user-friendly Linux distribution that promises to redefine the way we interact with our devices. With its focus on performance, security, and customization, Nitrux Linux presents a compelling case for those seeking to break free from the constraints of proprietary software and embrace the freedom and flexibility of open-source computing.
PHP Frameworks: I want to break free (IPC Berlin 2024)Ralf Eggert
In this presentation, we examine the challenges and limitations of relying too heavily on PHP frameworks in web development. We discuss the history of PHP and its frameworks to understand how this dependence has evolved. The focus will be on providing concrete tips and strategies to reduce reliance on these frameworks, based on real-world examples and practical considerations. The goal is to equip developers with the skills and knowledge to create more flexible and future-proof web applications. We'll explore the importance of maintaining autonomy in a rapidly changing tech landscape and how to make informed decisions in PHP development.
This talk is aimed at encouraging a more independent approach to using PHP frameworks, moving towards a more flexible and future-proof approach to PHP development.
Essentials of Automations: The Art of Triggers and Actions in FMESafe Software
In this second installment of our Essentials of Automations webinar series, we’ll explore the landscape of triggers and actions, guiding you through the nuances of authoring and adapting workspaces for seamless automations. Gain an understanding of the full spectrum of triggers and actions available in FME, empowering you to enhance your workspaces for efficient automation.
We’ll kick things off by showcasing the most commonly used event-based triggers, introducing you to various automation workflows like manual triggers, schedules, directory watchers, and more. Plus, see how these elements play out in real scenarios.
Whether you’re tweaking your current setup or building from the ground up, this session will arm you with the tools and insights needed to transform your FME usage into a powerhouse of productivity. Join us to discover effective strategies that simplify complex processes, enhancing your productivity and transforming your data management practices with FME. Let’s turn complexity into clarity and make your workspaces work wonders!
Securing your Kubernetes cluster_ a step-by-step guide to success !KatiaHIMEUR1
Today, after several years of existence, an extremely active community and an ultra-dynamic ecosystem, Kubernetes has established itself as the de facto standard in container orchestration. Thanks to a wide range of managed services, it has never been so easy to set up a ready-to-use Kubernetes cluster.
However, this ease of use means that the subject of security in Kubernetes is often left for later, or even neglected. This exposes companies to significant risks.
In this talk, I'll show you step-by-step how to secure your Kubernetes cluster for greater peace of mind and reliability.
Generative AI Deep Dive: Advancing from Proof of Concept to ProductionAggregage
Join Maher Hanafi, VP of Engineering at Betterworks, in this new session where he'll share a practical framework to transform Gen AI prototypes into impactful products! He'll delve into the complexities of data collection and management, model selection and optimization, and ensuring security, scalability, and responsible use.
Smart TV Buyer Insights Survey 2024 by 91mobiles.pdf91mobiles
91mobiles recently conducted a Smart TV Buyer Insights Survey in which we asked over 3,000 respondents about the TV they own, aspects they look at on a new TV, and their TV buying preferences.
Pushing the limits of ePRTC: 100ns holdover for 100 daysAdtran
At WSTS 2024, Alon Stern explored the topic of parametric holdover and explained how recent research findings can be implemented in real-world PNT networks to achieve 100 nanoseconds of accuracy for up to 100 days.
LF Energy Webinar: Electrical Grid Modelling and Simulation Through PowSyBl -...DanBrown980551
Do you want to learn how to model and simulate an electrical network from scratch in under an hour?
Then welcome to this PowSyBl workshop, hosted by Rte, the French Transmission System Operator (TSO)!
During the webinar, you will discover the PowSyBl ecosystem as well as handle and study an electrical network through an interactive Python notebook.
PowSyBl is an open source project hosted by LF Energy, which offers a comprehensive set of features for electrical grid modelling and simulation. Among other advanced features, PowSyBl provides:
- A fully editable and extendable library for grid component modelling;
- Visualization tools to display your network;
- Grid simulation tools, such as power flows, security analyses (with or without remedial actions) and sensitivity analyses;
The framework is mostly written in Java, with a Python binding so that Python developers can access PowSyBl functionalities as well.
What you will learn during the webinar:
- For beginners: discover PowSyBl's functionalities through a quick general presentation and the notebook, without needing any expert coding skills;
- For advanced developers: master the skills to efficiently apply PowSyBl functionalities to your real-world scenarios.
Epistemic Interaction - tuning interfaces to provide information for AI supportAlan Dix
Paper presented at SYNERGY workshop at AVI 2024, Genoa, Italy. 3rd June 2024
https://alandix.com/academic/papers/synergy2024-epistemic/
As machine learning integrates deeper into human-computer interactions, the concept of epistemic interaction emerges, aiming to refine these interactions to enhance system adaptability. This approach encourages minor, intentional adjustments in user behaviour to enrich the data available for system learning. This paper introduces epistemic interaction within the context of human-system communication, illustrating how deliberate interaction design can improve system understanding and adaptation. Through concrete examples, we demonstrate the potential of epistemic interaction to significantly advance human-computer interaction by leveraging intuitive human communication strategies to inform system design and functionality, offering a novel pathway for enriching user-system engagements.
The Metaverse and AI: how can decision-makers harness the Metaverse for their...Jen Stirrup
The Metaverse is popularized in science fiction, and now it is becoming closer to being a part of our daily lives through the use of social media and shopping companies. How can businesses survive in a world where Artificial Intelligence is becoming the present as well as the future of technology, and how does the Metaverse fit into business strategy when futurist ideas are developing into reality at accelerated rates? How do we do this when our data isn't up to scratch? How can we move towards success with our data so we are set up for the Metaverse when it arrives?
How can you help your company evolve, adapt, and succeed using Artificial Intelligence and the Metaverse to stay ahead of the competition? What are the potential issues, complications, and benefits that these technologies could bring to us and our organizations? In this session, Jen Stirrup will explain how to start thinking about these technologies as an organisation.
State of ICS and IoT Cyber Threat Landscape Report 2024 previewPrayukth K V
The IoT and OT threat landscape report has been prepared by the Threat Research Team at Sectrio using data from Sectrio, cyber threat intelligence farming facilities spread across over 85 cities around the world. In addition, Sectrio also runs AI-based advanced threat and payload engagement facilities that serve as sinks to attract and engage sophisticated threat actors, and newer malware including new variants and latent threats that are at an earlier stage of development.
The latest edition of the OT/ICS and IoT security Threat Landscape Report 2024 also covers:
State of global ICS asset and network exposure
Sectoral targets and attacks as well as the cost of ransom
Global APT activity, AI usage, actor and tactic profiles, and implications
Rise in volumes of AI-powered cyberattacks
Major cyber events in 2024
Malware and malicious payload trends
Cyberattack types and targets
Vulnerability exploit attempts on CVEs
Attacks on counties – USA
Expansion of bot farms – how, where, and why
In-depth analysis of the cyber threat landscape across North America, South America, Europe, APAC, and the Middle East
Why are attacks on smart factories rising?
Cyber risk predictions
Axis of attacks – Europe
Systemic attacks in the Middle East
Download the full report from here:
https://sectrio.com/resources/ot-threat-landscape-reports/sectrio-releases-ot-ics-and-iot-security-threat-landscape-report-2024/
UiPath Test Automation using UiPath Test Suite series, part 4DianaGray10
Welcome to UiPath Test Automation using UiPath Test Suite series part 4. In this session, we will cover Test Manager overview along with SAP heatmap.
The UiPath Test Manager overview with SAP heatmap webinar offers a concise yet comprehensive exploration of the role of a Test Manager within SAP environments, coupled with the utilization of heatmaps for effective testing strategies.
Participants will gain insights into the responsibilities, challenges, and best practices associated with test management in SAP projects. Additionally, the webinar delves into the significance of heatmaps as a visual aid for identifying testing priorities, areas of risk, and resource allocation within SAP landscapes. Through this session, attendees can expect to enhance their understanding of test management principles while learning practical approaches to optimize testing processes in SAP environments using heatmap visualization techniques
What will you get from this session?
1. Insights into SAP testing best practices
2. Heatmap utilization for testing
3. Optimization of testing processes
4. Demo
Topics covered:
Execution from the test manager
Orchestrator execution result
Defect reporting
SAP heatmap example with demo
Speaker:
Deepak Rai, Automation Practice Lead, Boundaryless Group and UiPath MVP
Transcript: Selling digital books in 2024: Insights from industry leaders - T...BookNet Canada
The publishing industry has been selling digital audiobooks and ebooks for over a decade and has found its groove. What’s changed? What has stayed the same? Where do we go from here? Join a group of leading sales peers from across the industry for a conversation about the lessons learned since the popularization of digital books, best practices, digital book supply chain management, and more.
Link to video recording: https://bnctechforum.ca/sessions/selling-digital-books-in-2024-insights-from-industry-leaders/
Presented by BookNet Canada on May 28, 2024, with support from the Department of Canadian Heritage.
2. Contents
1.1. Executive Summary
Executive Summary
1.1 Overview of Findings
1.2 Structure of the Report
1.3 Research and Analysis Methods
1.4 Glossary of Terms in this Report
2.2. Introduction to Translational Regenerative Medicine
Introduction to Translational Regenerative Medicine
2.1 What is Translational Regenerative Medicine?
2.2 Translational Regenerative Medicine: Market Segmentation
2.2.1 Stem Cell Therapy
2.2.1.1 Classifying Stem Cells by Potency
2.2.1.2 Categories of Stem Cells
2.2.1.3 Autologous versus Allogeneic Stem Cells: Towards Universal Stem Cell Products?
2.2.1.4 Stem Cell Therapeutic Applications
2.2.2 Tissue Engineering
2.2.3 Gene Therapy
2.2.3.1 Harnessing Infectivity: Viral Vectors in Gene Therapy
2.3 Other Areas of Regenerative Medicine
2.3.1 Small Molecules and Proteins – Enhancing Regenerative Medicine
2.3.2 Cosmetic Applications of Regenerative Medicine
2.4 Regulation of Regenerative Medicine
2.4.1 Regulation of Regenerative Medicine Products in Europe
2.4.2 Regulation of Regenerative Medicine Products in the US
2.5 Phases of Clinical Trials
www.visiongain.com
3. Contents
2.6 Scope of this Report
2.6.1 Products Excluded from this Report
3.3. Regenerative Medicine: World Market 2014-2024
Regenerative Medicine: World Market 2014-2024
3.1 The World Regenerative Medicine Market in 2012 and 2013
3.2 Leading Regenerative Medicine Products
3.3 Leading Companies in the Regenerative Medicine Market
3.4 World Regenerative Medicine Market: Sales Forecast 2014-2024
3.4.1 Regenerative Medicine Market Segments: Sales Forecasts 2014-2024
3.4.2 Regenerative Medicine: CAGRs by Segment 2014-2024
3.4.3 Changing Market Shares by Segment 2014-2024
3.5 Stem Cell Therapies Lead the Regenerative Medicine Market
3.5.1 Stem Cells Therapy Market: Drivers and Restraints 2014-2024
3.6 Tissue Engineered Products Will Continue Strong Growth
3.6.1 Tissue Engineered Products Market: Drivers and Restraints 2014-2024
3.7 Gene Therapies Show High Growth Potential
3.7.1 Gene Therapy Market: Drivers and Restraints 2014-2024
4.4. Leading National Markets 2014-2024
Leading National Markets 2014-2024
4.1 Regional Breakdown of the World Regenerative Medicine Market
4.2 World Regenerative Medicine Market: Regional Forecast 2014-2024
4.2.1 Regenerative Medicine: CAGRs by Regional Market 2014-2024
4.2.2 How Will Regional Market Shares Change to 2024?
www.visiongain.com
4. Contents
4.3 The US Regenerative Medicine Market 2014-2024
4.3.1 US Regenerative Medicine Market: Drivers and Restraints
4.3.2 US Market Overview: The Leading Regenerative Medicine Market
4.3.2.1 Regulation of Regenerative Medicine in the US
4.3.2.2 Embryonic Stem Cell Research Remains Controversial
4.3.2.3 An End to Patents on Human Genes?
4.4 The European Regenerative Medicine Market 2014-2024
4.4.1 European Regenerative Medicine Market: Drivers and Restraints
4.4.2 European Market Overview: A Strong Science Base
4.4.2.1 On the Brink of a Unitary European Patent System
4.4.2.2 Regulation of Regenerative Medicine in Europe
4.4.2.3 European REMEDiE Project
4.4.2.4 A UK Perspective on the Regenerative Medicine Market
4.4.2.5 Developments in the Russian Regenerative Medicine Market
4.5 The Asia-Pacific Regenerative Medicine Market 2014-2024
4.5.1 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints
4.5.2 Asia-Pacific Market Overview: Towards Rapid Commercialisation
4.5.2.1 Japan: Transforming the Regulatory Landscape
4.5.2.2 China: Encouraging Stem Cell R&D
4.5.2.3 India: An Emerging RM Industry
4.5.2.4 South Korea: First to Approve Stem Cell Treatments
4.5.2.5 Australia: Encouraging Translational Regenerative Medicine
4.6 The Regenerative Medicine Market in the Rest of the World 2014-2024
4.6.1 Brazil – An Emerging Market in South America
www.visiongain.com
5. Contents
5.5. Leading Companies in the Regenerative Medicine Market
Leading Companies in the Regenerative Medicine Market
5.1 Aastrom Biosciences: Developing Cardiovascular Stem Cell Therapies
5.1.1 Aastrom Biosciences: Clinical Trials
5.1.2 Aastrom Biosciences: Products in Development
5.1.2.1 Ixmyelocel-T: Autologous Mesenchymal Stem Cell Therapy
5.2 Advanced Cell Technology: Stem Cells for Eye Diseases
5.2.1 Advanced Cell Technology: Clinical Trials
5.2.2 Advanced Cell Technology: Products in Development
5.2.2.1 Retinal Pigment Epithelial Cell Therapy
5.2.2.2 iPSC-derived Platelets
5.2.2.3 Hemangioblast Program
5.2.2.4 Mesenchymal Stem Cell Program
5.2.2.5 Other Products
5.3 Alphatec Spine: Bone Allgrafts
5.3.1 Alphatec Spine: Clinical Trials
5.3.2 Alphatec Spine: Products in Development
5.4 Anterogen: South Korean Stem Cell Company
5.4.1 Anterogen: Clinical Trials
5.4.2 Anterogen: Products in Development
5.5 Athersys: Developing Allogeneic Progenitor Cell Therapy
5.5.1 Athersys: Clinical Trials
5.5.2 Athersys: Products in Development
5.5.2.1 MultiStem: Allogeneic Multipotent Adult Progenitor Cells
www.visiongain.com
6. Contents
5.5.2.2 Serotonin Receptor Agonists
5.6 Avita Medical: Spray-On Skin Cell Therapy
5.6.1 Avita Medical: Clinical Trials
5.7 AxoGen: Nerve Regeneration Products
5.7.1 AxoGen: Clinical Trials
5.7.2 AxoGen: Products in Development
5.8 Genzyme (acquired by Sanofi): A Leader in Regenerative Medicine
5.8.1 Genzyme: Clinical Trials
5.8.2 Genzyme: Products in Development
5.9 Medipost: Cartilage Repair with Cartistem
5.9.1 Medipost: Clinical Trials
5.9.2 Medipost: Products in Development
5.10 Mesoblast: An Australian RM Leader
5.10.1 Mesoblast : Clinical Trials
5.10.2 Mesoblast: Products in Development
5.10.2.1 NeoFuse
5.10.2.2 Prochymal
5.10.2.3 Chondrogen
5.10.2.4 Mesenchymal Precursor Cells in Congestive Heart Failure
5.10.2.5 Other Pipeline Products
5.11 NuVasive: Spinal Surgery Bone Allografts
5.11.1 NuVasive: Clinical Trials
5.11.2 NuVasive: Products in Development
5.12 Organogenesis: a Tissue Engineering Pioneer
www.visiongain.com
7. Contents
5.12.1 Organogenesis: Clinical Trials
5.12.2 Organogenesis: Products in Development
5.13 Osiris Therapeutics: a Leading Stem Cell Company
5.13.1 Osiris Therapeutics: Clinical Trials
5.13.2 Osiris Therapeutics: Products in Development
5.14 Pharmicell: South Korean Stem Cell Leader
5.14.1 Pharmicell: Clinical Trials
5.14.2 Pharmicell: Products in Development
5.15 Regenerys: Manufacturing Skin Substitutes
5.15.1 Regenerys: Clinical Trials
5.15.2 Regenerys: Products in Development
5.16 Shire Regenerative Medicine: Entering the RM Market
5.16.1 Shire: Clinical Trials
5.16.2 Shire: Products in Development
5.16.2.1 Vascugel
5.17 TiGenix: European Cell Therapy Leader
5.17.1 TiGenix: Clinical Trials
5.17.2 TiGenix: Products in Development
5.18 UniQure: First Gene Therapy Approved in Europe
5.18.1 UniQure: Clinical Trials
5.18.2 UniQure: Products in Development
6.6. Stem Cell Therapy: Leading Applications 2014-2024
Stem Cell Therapy: Leading Applications 2014-2024
6.1 Stem Cell Therapy: Currently Available Therapies
www.visiongain.com
9. Contents
6.2.2 Diabetes and Stem Cell Therapy
6.2.2.1 Mesenchymal Precursor Cells (Mesoblast)
6.2.2.2 VC-01 (ViaCyte)
6.2.3 Cardiovascular Disease and Stem Cell Therapy
6.2.3.1 Endometrial Regenerative Cells (Medistem)
6.2.3.2 AMR-001 (NeoStem)
6.2.3.3 CAP-1002 (Capricor)
6.2.4 Stem Cell Therapy in Cancer
6.2.4.1 CLT-008 (Cellerant Therapeutics)
6.2.4.2 OncoCyte/BioTime – Targeting Cancer with Gene and Stem Cell Therapy
6.2.5 Stem Cell Therapy for CNS Conditions
6.2.5.1 NurOwn (BrainStorm Cell Therapeutics)
6.2.5.2 NSI-566 (Neuralstem)
6.2.5.3 MultiStem (Athersys)
6.2.5.4 PDA-001 (cenplacel-L, Celgene)
6.2.5.5 ALD-401 (Cytomedix)
6.2.5.6 ReN001 (ReNeuron)
6.2.6 Stem Cell Therapy for Eye Diseases
6.2.6.1 MA09-hRPE (Advanced Cell Technology)
6.2.6.2 HuCNS-SC (StemCells, Inc.)
6.2.6.3 EC200 (EyeCyte)
6.2.6.4 Pfizer’s Collaboration with The London Project to Cure Blindness
www.visiongain.com
10. Contents
7.7. Tissue Engineering: Leading Applications 2014-2024
Tissue Engineering: Leading Applications 2014-2024
7.1 Tissue Engineering: Currently Available Therapies
7.1.1 Tissue Engineering for Wound Repair
7.1.1.1 Apligraf (Organogenesis): Sales Forecast 2014-2024
7.1.1.2 BioDfence and BioDfactor (BioD)
7.1.1.3 CureXcell (MacroCure)
7.1.1.4 Dermagraft (Shire): Sales Forecast 2014-2024
7.1.1.5 Epicel (Sanofi)
7.1.1.6 Grafix (Osiris Therapeutics)
7.1.1.7 MySkin and CyroSkin (Regenerys)
7.1.1.8 ReCell (Avita Medical): Sales Forecast 2014-2024
7.1.2 Tissue Engineering for Cartilage Repair: Autologous Chondrocyte Implantation
7.1.2.1 Carticel (Sanofi)
7.1.2.2 ChondroCelect (TiGenix)
7.1.2.3 DeNovo NT (Zimmer)
7.1.2.4 MACI (Sanofi)
7.1.3 Other Available Tissue Engineering Therapies
7.1.3.1 Autologous Cultured Cell and Tissue Products (Japan Tissue Engineering Co.)
7.1.3.2 Gintuit (Organogenesis)
7.1.3.3 LAVIV (azficel-T, Fibrocell Science)
7.1.3.4 Acellular Tissue Engineering Products
7.2 Tissue Engineering Pipeline to 2024
7.2.1 Autologous Chondrocyte Implantation Pipeline
7.2.2 Tissue Engineering for Skin
www.visiongain.com
11. Contents
7.2.3 Tissue Engineering for Liver Disease
7.2.3.1 Extracorporeal Bio-Artificial Liver Therapy (Vital Therapies)
7.2.4 Tissue Engineering for Cardiovascular Disease
7.2.5 Tissue Engineering for Eye Diseases
7.2.6 Prospects for Organ Transplantation
8.8. Gene Therapy: Leading Applications 2014-2024
Gene Therapy: Leading Applications 2014-2024
8.1 Gene Therapy: Currently Available Therapies
8.1.1 Gendicine (Benda Pharmaceutical)
8.1.2 Oncorine (Shanghai Sunway Biotech)
8.1.3 Neovasculgen (Human Stem Cells Institute)
8.1.4 Neovasculgen (HSCI): Sales Forecast 2014-2024
8.1.5 Glybera (UniQure)
8.2 Withdrawn From Sale: Rexin-G (Epeius Biotechnologies)
8.3 Gene Therapy Pipeline to 2024
8.3.1 Late-Stage Gene Therapy Pipeline
8.3.1.1 Collategene (beperminogene perplasmid, AnGes MG/Vical)
8.3.1.2 ProstAtak (AdV-tk, Advantagene)
8.3.1.3 Trinam (taberminogene vadenovec, Ark Therapeutics)
8.3.1.4 TVEC (talimogene laherparepvec, Amgen)
8.3.1.5 AAV2-hRPE65v2 (Spark Therapeutics)
8.3.1.6 CG0070 (Cold Genesys)
8.3.2 Gene Therapy for Diabetes
8.3.3 Gene Therapy for Cancer
www.visiongain.com
12. Contents
8.3.4 Gene Therapy for Neurological Diseases
8.3.5 Gene Therapy for Haemophilia B
9.9. Qualitative Analysis of the Regenerative Medicine Market 2014Qualitative Analysis of the Regenerative Medicine Market 2014-2024
2024
9.1 SWOT Analysis of the Regenerative Medicine Market
9.2 Strengths
9.2.1 Incremental Progress in Research
9.2.2 Regulatory Frameworks Improving
9.2.3 An Established Route to Market
9.2.4 Strong Support from National Governments
9.3 Weaknesses
9.3.1 Lack of Venture Capital
9.3.2 High Costs of RM Therapies
9.3.3 Commercialisation Requires New Business Models
9.3.4 Lack of Standardisation
9.4 Opportunities
9.4.1 Disruptive RM Therapies Can Create New Markets
9.4.2 3D Bioprinting and Other Technologies May Enable Rapid Scale-Up
9.4.3 Increasing Burden of Chronic Disease
9.4.4 Medical Tourism Can Drive the Market
9.5 Threats
9.5.1 Restraints on Reimbursement
9.5.2 Difficulty Establishing an Evidence Base
www.visiongain.com
13. Contents
9.5.3 Ethical Concerns Limiting R&D
9.5.4 Progress May be Slow
9.6 Porter’s Five Forces Analysis of the Regenerative Medicine Market
9.6.1 Rivalry Among Competitors [Medium]
9.6.2 Threat of New Entrants [Medium]
9.6.3 Power of Suppliers [Low]
9.6.4 Power of Buyers [Low]
9.6.5 Threat of Substitutes [High]
10. Research Interviews
10. Research Interviews
10.1 Interview with Dr Alan Trounson, President, California Institute for Regenerative Medicine
(CIRM)
10.1.1 Improved Funding in the Stem Cells Field
10.1.2 MSCs: Major Potential or Merely a Placeholder?
10.1.3 CIRM Investment Strategies
10.1.4 The Changing Regulatory Environment Worldwide
10.1.5 Key Trends for the Next Five to Ten Years
10.2 Interview with Professor Francois Berthiaume, Associate Professor of Biomedical
Engineering, Rutgers University, New Jersey
10.2.1 On the Regenerative Medicine Market
10.2.2 On the Future of Stem Cell Therapies
10.2.3 Challenges in the Tissue Engineering Market
10.2.4 Thoughts on Future Developments
10.3 Interview with Dr William Dolphin, CEO, Avita Medical, UK
www.visiongain.com
14. Contents
10.3.1 Future Prospects for the Regenerative Medicine Market
10.3.2 Is Regenerative Medicine Ready For Commercialisation?
10.3.3 On Emerging Regenerative Medicine Markets
10.3.4 Future Therapeutic Areas
10.3.5 Barriers to Developing Regenerative Medicine?
10.3.6 Thoughts on Future Developments
11. Conclusions
11. Conclusions
11.1 The World Regenerative Medicine Market in 2012 and 2013
11.1.1 Current Leading Regenerative Medicine Segments
11.1.2 Leading Regenerative Medicine Products
11.1.3 Leading Regenerative Medicine Companies
11.1.4 Leading Regional Markets
11.2 World Regenerative Medicine Market Forecast 2014-2024
11.3 Regenerative Medicine Late-Stage Pipeline
11.4 The Future of the Regenerative Medicine Market?
www.visiongain.com
15. Contents
List of Tables
Table 1.1 Currency Exchange Rates, 2012
Table 2.1 European Union Definitions of Regenerative Medicine Products, 2013
Table 2.2 Potency and Source of Stem Cells, 2013
Table 2.3 Germ Layers and Their Associated Cells, Tissues and Organs, 2013
Table 2.4 Stem Cell Categories, 2013
Table 2.5 Stem Cell Donor Terminology, 2013
Table 2.6 Clinical Trial Phases
Table 3.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by
Segment, 2012
Table 3.2 Leading Regenerative Medicine Products: Revenues ($m), 2012
Table 3.3 Leading Companies in the Regenerative Medicine Market: Leading Products and Net
Revenues ($m), 2012
Table 3.4 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2012-2024
Table 3.5 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%)
by Segment, 2012-2018
Table 3.6 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%)
by Segment, 2018-2024
Table 3.7 World Regenerative Medicine Market: CAGR (%) by Segment, 2012-2018, 2018-2024
and 2012-2024
Table 3.8 Market Shares (%) of the Regenerative Medicine Market by Segment, 2012, 2018 and
2024
Table 3.9 Stem Cell Market: Revenues ($m) and Market Shares (%) by Subsegment, 2012
www.visiongain.com
16. Contents
Table 3.10 Stem Cell Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.11 Tissue Engineered Products Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2012-2024
Table 3.12 Gene Therapy Market: Commercial-Stage Products, 2013
Table 3.13 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2012-2024
Table 3.14 Gene Therapy Market Forecast: Revenues ($m), AGR (%), CAGR (%) by Product,
2012-2024
Table 4.1 World Regenerative Medicine Market: Revenues ($m) and Market Shares (%) by
Region, 2012
Table 4.2 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%)
by Region, 2012-2018
Table 4.3 World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%)
by Region, 2018-2024
Table 4.4 World Regenerative Medicine Market: CAGR (%) by Region, 2012-2018, 2018-2024
and 2012-2024
Table 4.5 Market Shares (%) of the Regenerative Medicine Market by Region in 2012, 2018 and
2024
Table 4.6 US Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR (%),
2012-2024
Table 4.7 European Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2012-2024
Table 4.8 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), AGR (%), CAGR
(%), 2012-2024
Table 4.9 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), AGR (%),
CAGR (%), 2012-2024
Table 5.1 Aastrom Biosciences: Regenerative Medicine Clinical Trials, 2013
www.visiongain.com
17. Contents
Table 5.2 Advanced Cell Technology: Regenerative Medicine Clinical Trials, 2013
Table 5.3 AlphaTec Spine: Regenerative Medicine Clinical Trials, 2013
Table 5.4 Anterogen: Regenerative Medicine Clinical Trials, 2013
Table 5.5 Athersys: Regenerative Medicine Clinical Trials, 2013
Table 5.6 Avita Medical: Regenerative Medicine Clinical Trials, 2013
Table 5.7 AxoGen: Regenerative Medicine Clinical Trials, 2013
Table 5.8 Genzyme: Products in the US Market, 2013
Table 5.9 Genzyme: Regenerative Medicine Clinical Trials, 2013
Table 5.10 Medipost: Regenerative Medicine Clinical Trials, 2013
Table 5.11 Mesoblast: Regenerative Medicine Clinical Trials, 2013
Table 5.12 NuVasive: Regenerative Medicine Clinical Trials, 2013
Table 5.13 Organogenesis: Regenerative Medicine Clinical Trials, 2013
Table 5.14 Osiris Therapeutics: Regenerative Medicine Clinical Trials, 2013
Table 5.15 Pharmicell: Regenerative Medicine Clinical Trials, 2013
Table 5.16 Regenerys: Regenerative Medicine Clinical Trials, 2013
Table 5.17 Shire: Regenerative Medicine Clinical Trials, 2013
Table 5.18 TiGenix: Regenerative Medicine Clinical Trials, 2013
Table 5.19 UniQure: Regenerative Medicine Clinical Trials, 2013
Table 6.1 Selected Currently Available Stem Cell Products, 2013
Table 6.2 FDA-Approved Cord Blood-Derived Stem Cell Products for HSCT, 2013
Table 6.3 Stages of Osteogenesis, 2013
Table 6.4 NuVasive: Osteocel Plus Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 6.5 Orthofix: Trinity ELITE Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
Table 6.6 Mesoblast: Prochymal Revenue Forecast ($m), AGR (%), CAGR(%), 2012-2024
www.visiongain.com
19. Contents
List of Figures
Figure 2.1 Brief History of Stem Cell Research, 1900-2000
Figure 2.2 Brief History of Tissue Engineering, 1900-2013
Figure 2.3 Examples of FDA-Approved Tissue Engineered Products
Figure 2.4 Brief History of Gene Therapy, 1970-2013
Figure 3.1 World Regenerative Medicine Market: Market Shares (%) by Segment, 2012
Figure 3.2 Leading Regenerative Medicine Products: Market Shares (%), 2012
Figure 3.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 3.4 World Regenerative Medicine Market Forecast: Revenues ($m) by Segment, 20122024
Figure 3.5 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2018
Figure 3.6 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2018-2024
Figure 3.7 World Regenerative Medicine Market Forecast: CAGR (%) by Segment, 2012-2024
Figure 3.8 World Regenerative Medicine Market: Market Shares (%) by Segment, 2018
Figure 3.9 World Regenerative Medicine Market: Market Shares (%) by Segment, 2024
Figure 3.10 Stem Cell Market: Market Shares (%) by Subsegment, 2012
Figure 3.11 Stem Cell Therapy Market Forecast: Revenues ($m), 2012-2024
Figure 3.12 Stem Cell Therapy Market: Drivers and Restraints, 2014-2024
Figure 3.13 Tissue Engineered Products Market Forecast: Revenues ($m), 2012-2024
Figure 3.14 Tissue Engineered Products Market: Drivers and Restraints, 2014-2024
Figure 3.15 Gene Therapy Market Forecast: Revenues ($m), 2012-2024
Figure 3.16 Gene Therapy Market: Market Shares (%) by Product, 2012
Figure 3.17 Gene Therapy Market: Market Shares (%) by Product, 2018
www.visiongain.com
20. Contents
Figure 3.18 Gene Therapy Market: Market Shares (%) by Product, 2024
Figure 3.19 Gene Therapy Market: Drivers and Restraints, 2014-2024
Figure 4.1 World Regenerative Medicine Market: Revenues ($m) by Region, 2012
Figure 4.2 World Regenerative Medicine Market: Market Shares (%) by Region, 2012
Figure 4.3 World Regenerative Medicine Market Forecast: Revenues ($m) by Region, 2012-2024
Figure 4.4 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2018
Figure 4.5 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2018-2024
Figure 4.6 World Regenerative Medicine Market Forecast: CAGR (%) by Region, 2012-2024
Figure 4.7 World Regenerative Medicine Market: Market Shares (%) by Region, 2018
Figure 4.8 World Regenerative Medicine Market: Market Shares (%) by Region, 2024
Figure 4.9 US Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.10 US Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.11 European Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.12 European Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.13 Asia-Pacific Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
Figure 4.14 Asia-Pacific Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Figure 4.15 Rest of the World Regenerative Medicine Market Forecast: Revenues ($m), 20122024
Figure 6.1 NuVasive: Osteocel Plus Revenue Forecast ($m), 2012-2024
Figure 6.2 Orthofix: Trinity ELITE Revenue Forecast ($m), 2012-2024
Figure 6.3 Mesoblast: Prochymal Revenue Forecast ($m), 2012-2024
Figure 7.1 Organogenesis: Apligraf Revenue Forecast ($m), 2012-2024
Figure 7.2 Shire: Dermagraft Revenue Forecast ($m), 2012-2024
Figure 7.3 Avita Medical: ReCell Revenue Forecast ($m), 2012-2024
www.visiongain.com
21. Contents
Figure 8.1 Human Stem Cells Institute: Neovasculgen Revenue Forecast ($m), 2012-2024
Figure 8.2 UniQure: Glybera Revenue Forecast ($m), 2012-2024
Figure 9.1 World 65+ Population Forecast: Size (m), 2013-2024
Figure 9.2 Porter’s Five Forces Analysis of the Regenerative Medicine Market, 2014-2024
Figure 11.1 World Regenerative Medicine Market: Revenues ($m) by Segment, 2012
Figure 11.2 World Regenerative Medicine Market: Revenues ($m) by Region, 2012
Figure 11.3 World Regenerative Medicine Market Forecast: Revenues ($m), 2012-2024
www.visiongain.com
22. Contents
Companies Listed
Aastrom Biosciences
Adiposet Ltd (merged into Regenerys)
Advanced BioHealing (acquired by Shire)
Advanced Cell Technology (ACT)
Advanced Tissue Sciences (ATS)
Advantagene
Allosource
AlphaTec Spine
Altrika (acquired by Regenerys)
Amedica
Amgen
Amorcyte (acquired by NeoStem)
Amorepacific Corporation
Amsterdam Molecular Therapeutics (predecessor of UniQure)
AnGes MG
Angioblast Systems (acquired by Mesoblast)
Anika Therapeutics
AnorMED (acquired by Genzyme)
Anterogen (subsidiary of Bukwang Pharm Co Ltd)
Arcarios B.V.
Ark Therapeutics
Arteriocyte
www.visiongain.com
23. Contents
Athersys
Avita Medical
AxoGen
AxoGen Corporation (merged into AxoGen)
Baxter International
Beike Biotechnology
Benda Pharmaceutical
BioD
Bioheart
BioMed Realty Trust, Inc.
BioSante Pharmaceuticals
BioTime
BioTissue
BioVex Group (acquired by Amgen)
Blackstone Medical (acquired by Orthofix)
Bluebird Bio
BrainStorm Cell Therapeutics Inc.
Bukwang Pharm Co Ltd
California Stem Cell
Capricor
Cardio3 BioSciences
CDI
Celgene
Cell Targeting
www.visiongain.com
25. Contents
Genpharm
Genzyme (subsidiary of Sanofi)
Geron
Histogenics
Humacyte
Human Stem Cells Institute
Insulete Inc
Introgen Therapeutics
ISTO Technologies
Japan Tissue Engineering Co. (J-TEC)
JCR Pharmaceuticals Co.
Johnson & Johnson
Kinetic Concepts Inc. (merging into KCI)
LecTec Corporation (merged into AxoGen)
LifeCell (merging into KCI)
Lincoln Park Capital
Lonza
MacroCure
Medipost
Medistem (formerly Medistem Laboratories)
Medtronic
Mesoblast
Mitsubishi Tanabe
Musculoskeletal Transplant Foundation (MTF)
www.visiongain.com
26. Contents
Myriad Genetics
Mytogen
National Marrow Donor Program (NMDP) (US)
NeoStem
Neuralstem
New York Blood Center
Nippon Zoki Pharmaceutical
NuVasive
OncoCyte (subsidiary of BioTime)
Organogenesis
Organovo
Oristem
Orthofix
Orthomimetics Ltd (acquired by TiGenix)
Osiris Theraeutics
Oxford BioMedica
Parcell Laboratories
Pervasis Therapeutics (acquired by Shire)
Pfizer
Pharmacells
Pharmicell (formerly FCB-Pharmicell)
Progenitor Cell Therapy (part of NeoStem)
Protek Group
Regenerys
www.visiongain.com
27. Contents
Reliance Life Sciences
ReNeuron
Reprobank
Roslin Cellab
RTI Surgical
Rusnano
Sangamo
Sanofi
Shanghai Qisheng
Shanghai Sunway Biotech
Shenzhen SiBiono GeneTech
Shire
Shire Regenerative Medicine (subsidiary of Shire)
Skye Orthobiologics
Sotex PharmFirm (subsidiary of Protek Group)
Spark Therapeutics
StemCells, Inc.
Stempeutics Research
Stratatech Corporation
Systagenix (merging into KCI)
TCA Cellular Therapy
Tengion
Teva Pharmaceutical Industries (Teva)
TiGenix
www.visiongain.com
28. Contents
UniQure
University of Colorado Cord Blood Bank
ViaCyte (formerly NovoCell)
Vical
Vindon Scientific
Visiomed Group (merged into Avita Medical)
Vital Therapies, Inc.
WKD Holding Oy
Xcellerex
Xenetic Biosciences
Zentrales Knochenmarkspender-Register Deutschland (German National Registry of Blood Stem
Cell Donors) (ZKRD)
Zimmer
www.visiongain.com
29. Contents
Other Organisations Mentioned in This Report
Arthritis Research UK
Associazione Infermieristica per lo Studio delle Lesioni Cutanee (Nursing Association for the
Study of Cutaneous Wounds) (AISLeC) (Italy)
Australian Regenerative Medicine Institute
Australian Research Council
Beijing Cancer Hospital
Boston University
British Heart Foundation
California Institute of Regenerative Medicine (CIRM)
Cambridge Stem Cell Biology Institute.
Care Quality Commission (CQC) (UK)
Catalan Institution for Research and Advanced Studies
Cha General Hospital (Seoul, South Korea)
Children's Hospital of Philadelphia
China Food and Drug Administration (CFDA, formerly SFDA)
Chinese Academy of Sciences
Department of Biotechnology (India)
Department of Health (UK)
Duke University School of Medicine
European Medicines Agency (EMA)
European Patent Office
Finnish Red Cross Blood Service
Food and Drug Administration of the Philippines
www.visiongain.com
30. Contents
Harvard Medical School
Haute Autorité de santé (HAS) (French National Authority for Health)
Health Canada
Heriot-Watt University
Human Fertilisation and Embryology Authorityy (HFEA) (UK)
Institute for Regenerative Medicine, Wake Forest University Baptist Medical Center
Institute of Biomedical Research and Innovation Hospital (Kobe, Japan)
International Society for Stem Cell Research
Internet Archive
Japan Patent Office
Japanese Society for Regenerative Medicine
Karolinska Institute
King Fahad Medical City (Saudi Arabia)
LifeSouth Community Blood Centers
London Project to Cure Blindness
Mayo Clinic
Medical Research Council (UK)
Medicines and Healthcare products Regulatory Agency (MHRA) (UK)
Ministry of Economy, Trade and Industry (METI) (Japan)
Ministry of Food and Drug Safety (MFDS, formerly KFDA) (South Korea)
Ministry of Health (China)
Ministry of Health, Labour and Welfare (MHLW) (Japan)
Ministry of Science and Technology (China)
Monash University
www.visiongain.com
31. Contents
Moorfields Eye Hospital
National Health and Medical Research Council (Australia)
National Institutes of Health (US)
National Tissue Engineering Center (NTEC) (China)
Northeast ALS consortium
Pharmaceuticals and Medical Devices Agency (PMDA) (Japan)
Riken Center for Developmental Biology
Russian Ministry of Healthcare and Social Development
Rutgers University
Saudi Food and Drug Authority
Scottish Centre for Regenerative Medicine
Singapore General Hospital
SSM Cardinal Glennon Children's Medical Center
St. Jude's Children Research Hospital
StemGen
SUNY Upstate Medical University
UCL Institute of Ophthalmology
United Nations' Department of Economic and Social Affairs
United States Food and Drug Administration (FDA)
Universitat Autònoma de Barcelona
University College London
University of Edinburgh MRC Centre for Regenerative Medicine
University of Michigan
University of Modena Centre for Regenerative Medicine
www.visiongain.com
32. Contents
University of Wisconsin
US Department of Defense
VA Northern California Health Care System
Weizmann Institute of Science (Rehovot, Israel)
Wellcome Trust
World Health Organization
www.visiongain.com
33. Translational Regenerative Medicine:
Market Prospects 2014-2024
A large proportion of cell therapy trials being based in the US.
•
The main restraints on growth are:
Stringent restrictions on human embryonic stem cell research and difficulties with funding,
•
despite recent improvements under the Obama administration; research involving the
destruction of embryos remains a significant moral issue in the US
Concerns among investors due to long and uncertain development times, in a market
•
which is relatively dependent on venture capital to fund product development
Falling R&D productivity and decreasing expenditure on scientific research in the US
•
compared to Europe and the Asia-Pacific regions.
Figure 4.10 summarises the drivers and restraints of the US regenerative medicine market from
2012 to 2024.
Figure 4.10 US Regenerative Medicine Market: Drivers and Restraints, 2014-2024
Restraints
Drivers
•
Increasing demand for treatments for
degenerative and chronic diseases
•
Restrictive environment for human
embryonic stem cell research
•
High concentration of biotech and
life-science funding available
•
Investors deterred by long and
uncertain product development
•
Large proportion of clinical trials
based in the US
•
Falling R&D productivity and
research expenditure
•
Regulatory processes improving
Source: visiongain 2013
4.3.2 US Market Overview: The Leading Regenerative Medicine Market
As the leading market in regenerative medicine by virtue of the number of companies, clinical trials
and product approvals and the funding available for companies and research, US dominance is set
www.visiongain.com
Page 86
34. Translational Regenerative Medicine:
Market Prospects 2014-2024
Table 5.17 Shire: Regenerative Medicine Clinical Trials, 2013
Start and
Intervention
End Dates
Sep 1994 NCT01181440
Dermagraft
Jan 1997
Dec 1998 NCT01181453
Dermagraft
Mar 2000
Celaderm (frozen
Jan 2007 NCT00399308
cultured epidermal
Apr 2008
allograft)
Jun 2009 NCT00909870
Dermagraft
Aug 2011
Apr 2010 NCT01099215
PVS-10200
Oct 2012
May 2010 NCT01891760
Dermagraft
Jun 2012
Oct 2011 - Dermagraft or Oasis
NCT01450943
Oct 2014
versus standard care
Identifier
Indication
Diabetic foot ulcer
III
Diabetic foot ulcer
III
Leg ulcer, varicose ulcer
I/II
Venous leg ulcer
III
Peripheral artery disease
I/II
Venous leg ulcer
III
Diabetic foot ulcer
(comparative
efficacy)
Dec 2012 NCT01749306 Dec 2013
Dermagraft (ABH001) Epidermolysis bullosa
(terminated)
Mar 2013 Vascugel (SRM003)
Aug 2014
Mar 2013 NCT01806584
Vascugel (SRM003)
Aug 2015
NCT01806545
Phase
III
Arteriovenous fistula
II
Arteriovenous graft
II
Source: visiongain 2013; ClinicalTrials.gov
5.16.2 Shire: Products in Development
5.16.2.1 Vascugel
In April 2012, Shire acquired Pervasis Therapeutics, obtaining the rights to the company’s cell
therapy, Vascugel (SHP613, formerly SRM003). Vascugel consists of allogeneic human aortic
endothelial cells cultured in a gelatine matrix (Gelfoam). The product is intended to facilitate the
vascular access surgery that patients with end-stage kidney disease undergo so that they can
receive haemodialysis. After this surgery, patients must wait several months on average for the
access site to ‘mature’ and even after maturation there is a high risk that vascular access will fail –
Shire claims that 60% fail within one year. Vascugel is placed outside the blood vessel at a
vascular access site during surgery to promote maturation of the access site and reduce the risk of
failure. The product has received Orphan Product and Fast Track designation from the FDA and
Orphan Product designation from the European Medicines Agency. Phase II clinical trials of
Vascugel are ongoing.
www.visiongain.com
Page 138
35. Translational Regenerative Medicine:
Market Prospects 2014-2024
Table 7.1 Selected Currently Available Tissue Engineering Products, 2013
Company
Avita Medical
Intervention
ReCell
Description
Autologous cell treatment
Human allograft derived from
amniotic tissue, morselised
Human allograft derived from
amniotic tissue, patch
Indication
Wound repair
BioD
BioDfactor
BioD
BioDfence
FibroCell Science
LAVIV
Autologous fibroblasts
Japan Tissue
Engineering Co.
(various tissue
products)
MacroCure
CureXcell
Organogenesis
Apligraf
Autologous cultured epidermis,
cartilage and corneal epithelium
Activated allogeneic white blood
cells
Living bi-layered skin substitute
Organogenesis
Gintuit
Allogeneic cultured keratinocytes Regeneration of
and fibroblasts in bovine collagen gum tissue
Osiris Therapeutics
Grafix
Allograft cellular matrix
Diabetic foot
ulcers, burns,
wound repair
Regenerys
CryoSkin
Monolayer of undifferentiated
allogeneic keratinocytes
Burns, ulcers, nonhealing wounds
Regenerys
MySkin
Cultured autologous epidermal
substitute
Burns, ulcers, nonhealing wounds
Sanofi
Carticel
Autologous chondrocyte
implantation
Cartilage repair
Sanofi
Epicel
Cultured epidermal autograft
Sanofi
MACI
Matrix-induced autologous
chondrocyte implantation
Shire
Dermagraft
Fibroblast-derived skin substitute
TiGenix
ChondroCelect
Autologous chondrocyte
implantation
Zimmer
DeNovo NT
Juvenile cartilage allograft tissue
Wound repair
Wound repair
Nasolabial fold
wrinkles
(various)
Wound repair
Wound repair
Wound repair in
severe burns
Cartilage repair
Diabetic foot
ulcers
Cartilage repair
Repair of focal
cartilage defects
Source: visiongain 2013; company reports
The gold standard of wound care remains the use of autologous skin grafts. This technique
requires removal of healthy skin from one area of the patient to implant in another. The clear
limitation of this treatment is the availability of healthy donor skin. For example, in burns victims, a
large amount of donor skin is often required as burns can cover large areas.
www.visiongain.com
Page 172